Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3201/eid2610.202551 http://scihub22266oqcxt.onion/10.3201/eid2610.202551 32723432!7510727!32723432     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Emerg+Infect+Dis 2020 ; 26 (10): 2353-2360 Nephropedia Template TP {{tp|p=32723432|t=2020. Nationwide External Quality Assessment of SARS-CoV-2 Molecular Testing, South Korea |pdf=|usr=}}{{32723432}} gab.com Text Nationwide External Quality Assessment of SARS-CoV-2 Molecular Testing, South Korea JO: Emerg Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32723432 #FOAvip External quality assessment (EQA) is essential for ensuring reliable test results, especially when laboratories are using assays authorized for emergency use for newly emerging pathogens. We developed an EQA panel to assess the quality of real-time reverse transcription PCR assays being used in South Korea to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the participation of 23 public health organization laboratories and 95 nongovernmental laboratories involved in SARS-CoV-2 testing, we conducted qualitative and semiquantitative performance assessments by using pooled respiratory samples containing different viral loads of SARS-CoV-2 or human coronavirus OC43. A total of 110 (93.2%) laboratories reported correct results for all qualitative tests; 29 (24.6%) laboratories had >1 outliers according to cycle threshold values. Our EQA panel identified the potential weaknesses of currently available commercial reagent kits. The methodology we used can provide practical experience for those planning to conduct evaluations for testing of SARS-CoV-2 and other emerging pathogens in the future. Twit Text FOAVip Nationwide External Quality Assessment of SARS-CoV-2 Molecular Testing, South Korea ????Emerg Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32723432 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32723432 #FOAvip English Wikipedia <ref>{{Cite pmid|32723432}}</ref> Nationwide External Quality Assessment of SARS-CoV-2 Molecular Testing, South Korea #MMPMID32723432 Sung H; Han MG; Yoo CK; Lee SW; Chung YS; Park JS; Kim MN; Lee H; Hong KH; Seong MW; Lee K; Chun S; Lee WG; Kwon GC; Min WK Emerg Infect Dis 2020[Oct]; 26 (10): 2353-2360 PMID32723432show ga External quality assessment (EQA) is essential for ensuring reliable test results, especially when laboratories are using assays authorized for emergency use for newly emerging pathogens. We developed an EQA panel to assess the quality of real-time reverse transcription PCR assays being used in South Korea to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the participation of 23 public health organization laboratories and 95 nongovernmental laboratories involved in SARS-CoV-2 testing, we conducted qualitative and semiquantitative performance assessments by using pooled respiratory samples containing different viral loads of SARS-CoV-2 or human coronavirus OC43. A total of 110 (93.2%) laboratories reported correct results for all qualitative tests; 29 (24.6%) laboratories had >1 outliers according to cycle threshold values. Our EQA panel identified the potential weaknesses of currently available commercial reagent kits. The methodology we used can provide practical experience for those planning to conduct evaluations for testing of SARS-CoV-2 and other emerging pathogens in the future. |Betacoronavirus/*isolation & purification[MESH] |COVID-19[MESH] |COVID-19 Testing[MESH] |COVID-19 Vaccines[MESH] |Clinical Laboratory Techniques/*standards[MESH] |Coronavirus Infections/*diagnosis[MESH] |Humans[MESH] |Laboratory Proficiency Testing[MESH] |Pandemics[MESH] |Pneumonia, Viral/*diagnosis[MESH] |Quality Assurance, Health Care[MESH] |RNA, Viral/*analysis[MESH] |Reagent Kits, Diagnostic/standards[MESH] |Real-Time Polymerase Chain Reaction/methods/*standards[MESH] |Republic of Korea[MESH] |Respiratory System/virology[MESH] |Reverse Transcriptase Polymerase Chain Reaction/methods/*standards[MESH]Nationwide External Quality Assessment of SARS-CoV-2 Molecular Testing(epmc).pdf DeepDyve Pubget Overpricing